Congenital Myasthenic Syndromes in Adult Neurology Clinic
Neurol 91:e1770-e1777, Kao, J.C.,et al, 2018
A Child with Delayed Motor Milestones and Ptosis
Neurol 88:e158-e163, Ghosh, P.S., 2017
Two Cases of Congenital Myasthenic Syndrome with Vocal Cord Paralysis
Neurol 84:1281-1282, Al-Shahoumi, R.,et al, 2015
Myasthenia in Pregnancy: Best Practice Guidelines from a UK Multispecialty Working Group
JNNP 85:538-543, Norwood, F.,et al, 2014
Congenital Myasthenic Syndromes
In:Neurologic Clinics, 12:401-4371994., Engel,A.G., 1994
Acetylcholine Receptor Antibodies in Juvenile Myasthenia Gravis
Neurol 43:977-982, Andrews,P.I.,et al, 1993
Ocular Pseudomyasthenia or Ocular Myasthenia'Plus':A Warning to Clinicians
Neurol 39:1150-1154, Moorthy,G.,et al, 1989
Myasthenia Gravis & Myasthenic Syndromes
Ann Neurol 16:519-534, Engel,A.G., 1984
Clinical Syndromes of Myasthenia in Infancy & Childhood
Arch Neurol 35:97, Fenichel,G.M., 1978
Familial Neuromuscular Disease with Type 1 Fiber Hypoplasia, Tubular Aggregates, Cardiomyopathy, & Myasthenic Features
Neurol 28:1135-1140, Dobkin,B.H.,et al, 1978
Myasthenia Gravis Following Dabrafenib and Trametinib for Metastatic Melanoma
Neurol 94:322-323, Zaloum, A.,et al, 2020
Neuromuscular Adverse Events Associated with Anti-PD-1 Monoclonal Antibodies
Neurol 92:663-674, Johansen, A.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Myasthenia Gravis after Botulinum Toxin Type A Injection
Turk J Neurol 22:143-144, Tekce, H.D.,et al, 2016
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Clinicopathologic Conference, Thymoma with Paraneoplastic Myasthenia Gravis, Polymyositis and Myocarditis, and Brain Stem Encephalitis
NEJM 365:2413-2422, Case 39-2011, 2011
Multifocal Paraneoplastic Cortical Encephalitis Associated With Myasthenia Gravis and Thymoma
Arch Neurol 66:1407-1409, Hammoud,K.,et al, 2009
A Case with Myasthenia Gravis, Brain Stem Multiple Infarcts, Fracture of Vertebrai Th6 and discal hernia to the Th7/Th8
Radiol Oncol 43:3:170-174, KuKaj,V.,et al, 2009
Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006
Plasma Exchange in Neuroimmunological Disorders: Part 2. Treatment of Neuromuscular Disorders
Arch Neurol 63:1066-1071, Lehmann,H.C.,et al, 2006
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Difference in Distribution of Muscle Weakness Between Myasthenia Gravis and the Lambert-Eaton Myasthenic Syndrome
JNNP 73:766-768, Wirtz,P.W.,et al, 2002
Brain Stem Compression by a Giant Vertebrobasilar Aneurysm Mimicking Seronegative Myasthenia
JNNP 71:125-126, Frisby,J.,et al, 2001
Neuroendocrine Lung Tumors and Disorders of the Neuromuscular Junction
Neurol 52:1490-1491, Burns,T.M.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
Drugs and Myasthenia Gravis, An Update
Arch Int Med 157:399-408, Wittbrodt,E.T., 1997
Treatment of Acquired Myasthenia Gravis
Neurol 48 (Suppl 5) :S46-S51997., Massey,J.M., 1997
Exacerbation of Myasthenia Gravis Associated with Cocaine Use
Neurol 46:271-272, Daras,M.,et al, 1996
Myasthenia Gravis During Interferon Alfa Therapy
Neurol 45:382-383, Batocchi,A.P.,et al, 1995
Myasthenic Symptoms in Patients with Mitochondrial Myopathies
Muscle & Nerve 18:1338-1340, LeForestier,N.,et al, 1995
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Ocular Myasthenia Gravis
J Natl Med Assoc 85:681-684, March,G.A.&Johnson,J.N., 1993
Aggravation of Myasthenia Gravis by Erythromycin
J Pediatr 119:155-156, Absher,J.R.&Bale,J.F., 1991
Myasthenia Gravis Unmasked by Cocaine Abuse
NEJM 325:892, Berciano,J.,et al, 1991
Neuromuscular Blockade
Lancet 335:382-384, , 1990
Aggravation of Myasthenia Gravis by Erythromycin
Ann Neurol 28:577-579, May,E.F.&Calvert,P.C., 1990
Adverse Drug Effects on Neuromuscular Transmission
Semin Neurol 10:89-102, Howard,J.F., 1990
Facioscapulohumeral Muscular Dystrophy, in Neuromuscular Disease
Springer-Verlag, NY, p289988., Swash,M.&Schwartz,M.S., 1988
Parkinson's Disease & Myasthenia Gravis:Adverse Effect of Trihexyphenidyl on Neuromuscular Transmission
Neurol 37:832-833, Ueno,S.,et al, 1987
Worsening of Myasthenia Gravis with Timolol Maleate Eyedrops
Ann Neurol 17:211-212, Verkijk,A., 1985
Abnormalities of Eyelid Closure
In Walsh & Hoyt's Clinical Neuro-ophthalmology, Williams & Wilkins, Baltimore, 2:967, Miller,M.R., 1985
Beta-Adrenoreceptor Antagonists & Diplopia
Lancet 2:826-827, Weber,J.C.P., 1982
Treatment with Oral 4-aminopyridine in Disorders of Neuromuscular Transmission
Neurol 31:265-271, Murray,N.M.F.,et al, 1981
Procainamide-Induced Myasthenia-like Weakness in a Patient with Peripheral Neuropathy
Arch Neurol 38:378-379, Niakan,E.,et al, 1981